About Dr. Stephanie Shieh, PharmD
Dr. Stephanie Shieh, PharmD was born in Kentucky and raised in Southern Los Angeles. She attended the Western University of Health Sciences and has been a practicing pharmacist for 7 years. The most rewarding part of her job is seeing her patients happy – whether it’s helping them understand their medication, catching a drug interaction, or being able to communicate with their doctor to improve their therapy. She is currently precepting students from Marshall B. Ketchum University. In her free time, she enjoys spending quality time with her husband and 2 daughters. They love playing outside, doing arts and crafts, and having family dinner.
Articles by Dr. Stephanie Shieh, PharmD
How Is TPN Administered?
Total parenteral nutrition (TPN) is a nutritional support method used to administer essential nutrients intravenously directly into a patient’s bloodstream rather than into the gastrointestinal tract. TPN solution includes nutrients like sugar, minerals, proteins, carbohydrates, lipids, vitamins, and electrolytes.
IVIG for Myasthenia Gravis
Myasthenia gravis (MG) is a chronic autoimmune disorder in which the body’s own antibodies destroy the communication between nerves and muscles, consequently weakening skeletal muscles. This condition can affect any of the voluntary muscles of the body, but certain muscle groups are more commonly affected than others.
IV Nutrition Therapy
IV nutrition therapy, also called parenteral nutrition (PN), is the intravenous administration of nutrients directly into the bloodstream. Because there are medical conditions (acute and chronic) that prevent patients from receiving oral nutrition, intravenous nutritional therapies are needed in many cases.
The term “myopathy” generally means muscle weakness, while the term “necrotizing” means cell death and necrosis. Necrotizing myopathy, also known as necrotizing autoimmune myopathy (NAM) or immune-mediated necrotizing myopathy (IMNM) is characterized by cell death and necrosis of muscle cells, particularly the muscles closer to the center of the body.
Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK), which are involved in the production and growth of red blood cells. In myelofibrosis (bone marrow cancer) or polycythemia vera (a rare blood disorder), the Janus kinases are overactive, which leads to uncontrolled production of blood cells that can migrate to other organs such as the spleen and cause enlargement. Ruxolitinib inhibits specific signaling pathways and thus stops this overproduction of blood cells.
Erlotinib, also known as Tarceva, is a targeted cancer drug used to treat metastatic non-small cell lung cancer (NSCLC) in patients with a specific gene mutation (EGFR exon 19 deletion or exon 21 [L858R] substitution mutations) as first-line therapy, maintenance treatment, or for progressive disease. It is also used to treat patients with locally advanced, unresectable, or metastatic pancreatic cancer. Lastly, it can be used for advanced papillary kidney cancer (off-label use).